Summary
The detection of specific genetic alterations in breast cancer is useful for diagnosing, predicting prognosis and planning preoperative treatment. c-erbB2/neu overexpression is usually detected by immunocytochemistry (ICC), although this technique is neither completely reproducible nor highly reliable, owing to specimen and methodologic variability and antibody sensitivity. Here, we combine two well-established techniques, fine-needle aspiration (FNA) and fluorescence in situ hybridization (FISH), to detect c-erbB2/neu amplification in patients candidate to primary chemotherapy and, in part, previously analysed for c-erbB2/neu overexpression. Sixty smears from FNA were used to simultaneously detect c-erbB2/neu and chromosome 17 centromere. FISH was successful in 58 cases and detected 24 amplified cases, three of which were negative by immunophenotyping, 28 negative cases, with evidence of two normal c-erbB2/neu/ signals, two cases with deletion of c-erbB2/neu, and four cases with polysomy, thus providing more reliable and informative results than ICC. This study underlines the advantages offered by the FNA and FISH combination which are two rapid, reliable, simple and informative techniques, to analyse one of the most important genetic markers for predicting prognosis and chemotherapy planning for breast carcinoma in particular in the light of the recently proposed trials of primary chemotherapy.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Alsabeh, R., Wilson, C. S., Ahn, C. W., Vasef, M. A. & Battifora, H. (1996). Expression of bcl-2 by breast cancer: a possible diagnostic application. Modern Pathol 9: 439–444.
Andrulis, I. L., Bull, S. B., Blackstein, M. E., Sutherland, D., Mak, C., Sidloffsky, S., Pritzker, K. P. H., Hartwick, R. W., Hanna, W., Lickley, L., Wilkinson, R., Qizilbash, A., Ambus, U., Lipa, M., Weizel, H., Katz, A., Baida, M., Mariz, S., Stoik, G., Dacamara, P., Strongitham, D., Geddie, W. & McCready, D. (1998). neu/erB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol 16: 1340–1349.
Baselga, J., Tripathy, D., Mendelsohn, J., Baugham, S., Benz, C. C., Dantis, L., Sklarin, N. T., Bobrow, L. G., Happerfield, L. C. & Millis, R. R. (1996). Comparison of immunohistological staining with different antibodies to the c-erbB-2 oncoprotein. Appl Immunohistochem 4: 128–134.
Bonadonna, G., Veronesi, U., Brambilla, C., Ferrari, L., Luini, A., Greco, M., Bartoli, C., Coopmans de Yoldi, G., Zucali, L., Rilke, F., Andreola, S., Silvestrini, R., Di Fronzo, G. & Valugussa, G. (1990). Primary chemotherapy to avoid mastectomy in tumours with diameters of three centimeters or more. J Natl Cancer Inst 82: 1548–1545.
Cajulis, R. S., Frias-Hidvegi, D., Gordon, H. Y. & Eggena, S. (1996). Detection of numerical chromosome abnormalities by fluorescence in situ hybridization of interphase cell nuclei with chromosome-specific probes on archival cytological samples. Diagn Cytopathol 14: 178–181.
Corkill, M. E. & Katz, R. (1994). Immunocytochemical staining of c-erb B-2 oncogene in fine-needle aspirates of breast carcinoma: a comparison with tissue sections and other breast cancer prognostic factors. Diagn Cytopathol 11: 250–254.
De Potter, C. R. & Schelfhout, A. M. (1995). The neu-protein and breast cancer. Virch Arch 426: 107–115.
De Potter, C. R., Quatacker, J., Maertens, G., Van Daele, S., Pauwels, C., Verhofstede, C., Eechaute, W. & Roels, H. (1989). The subcellular localization of the neu protein in human normal and neoplastic cells. Int J Cancer 44: 969–974.
Frigo, B., Pilotti, S., Zurrida, S., Ermellino, L., Manzari, A. & Rilke, F. (1995). Analysis of estrogen and progesterone receptors on preoperative fine needle aspirates. Breast Cancer Res Treat 33: 179–184.
Gnant, M., Blijham, G. & Reiner, A. (1993). Aneuploid fraction but not DNA index is important for the prognosis of patients with stage I and II breast cancer: 10 year result. Ann Oncol 4: 643–650.
Goldhirsch, A., Wood, W. C., Senn, H. J., Glick, J. H. & Gelber, R. D. (1995). Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 87: 1441–1445.
Gusterson, B. A., Gelber, R. D., Goldhirsch, A., Price, K. N., Save-Soderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C. M., Golouh, R., Reed, R., Martinez-Tello, F., Tiltman, A., Torhorst, J., Grigolato, P., Bettelheim, R., Neville, A. M., Burki, K., Castiglione, M., Collins, J., Lindtner, J. & Senn, H. J. (1992). Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10: 1049–1056.
Hansen, R., Reddel, R. & Braithwaite, A. (1995). The transforming oncoproteins determine the mechanism by which p53 suppresses cell transformation: pRb-mediated growth arrest or apoptosis. Oncogene 11: 2535–2545.
Harwerth, I. M., Wels, W., Schlegel, J., Muller, M. & Hynes, N. E. (1993). Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br J Cancer 68: 1140–1145.
Hynes, N. E. & Stern, D. F. (1994). The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198: 165–184.
Kallionemi, O. P., Kallionemi, A., Kurisu, W., Thor, A., Chen, L. C., Smith, H. S., Waldman, F. M., Pinkel, D. & Gray, J. W. (1992). ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 89: 5321–5325.
Koss, L. G. (1979a). Diagnostic Cytology and its Histopathologic Bases, vol. 2, 3rd edn, pp. 1211–1222 Lippincott: Philadelphia–Toronto
Koss, L. G. (1979b). Diagnostic Cytology and its Histopathologic Bases, vol. 2, 3rd edn, pp. 1006–1241. Lippincott: Philadelphia–Toronto
Lavarino, C., Corletto, V., Mezzelani, A., Della Torre, G., Bartoli, C., Riva, C., Pierotti, M. A., Rilke, F. & Pilotti, S. (1998). Detection of TP53 mutation, loss of heterozygosity and DNA content in breast carcinoma fine-needle aspiration. Br J Cancer 77: 125–130.
Lichter, P., Chang Tang, C., Call, K., Hermanson, G., Evans, G. A., Housman, D. & Ward, D. C. (1990). High-resolution mapping of human chromosome 11 by in situ hybridization with cosmid clones. Science 247: 64–67.
Ljung, B. M., Chew, K., Deng, G., Matsumura, K., Waldman, F. & Smith, H. (1994). Fine needle aspiration techniques for the characterization of breast cancers. Cancer 74: 1000–1005.
Lonn, U., Lonn, S., Nilsson, B. & Stenkvist, B. (1996). Prognostic significance of c-erb-B2 amplification in fine-needle biopsies of breast cancer patients not operated at diagnosis. Breast Cancer Res Treat 39: 213–220.
Lowe, S. W., Ruley, H. E., Jacks, T. & Housman, D. E. (1993). p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957–967.
Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fischer, D. E., Housman, D. E. & Jacks, T. (1994). p53 status and efficacy of cancer therapy in vivo. Science 266: 807–810.
Midulla, C., Giovagnoli, M. R., Valli, C. & Vecchione, A. (1995). Correlation between ploidy status ERB-B2 and P53 immunohistochemical expression in primary breast carcinoma. Analyt Quant Cytol Histol 17: 157–162.
Moll, U. M., Ostermeyer, A. G., Ahomadegbe, J. C., Mathieu, M. C. & Riou, G. (1995). p53 mediated tumour cell response to chemotherapeutic DNA damage: a preliminary study in matched pairs of breast cancer biopsies. Hum Pathol 26: 1293–1301.
Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M. & Handerson, C. (1994). c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1330: 1260–1266.
Pietras, R. J., Arboleda, J., Reese, D. M., Wongvipat, N., Pegram, M. D., Ramos, L., Gorman, C. M., Parker, M. G., Sliwkowski, M. X. & Slamon, D. J. (1995). HER-2 tyrosine kinase pathway targets estrogen receptor and promoters hormone-independent growth in human breast cancer cells. Oncogene 10: 2435–2446.
Press, M. F., Hung, G., Godolphin, W. & Slamon, D. J. (1994). Sensitivity of c-erbB2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54: 2771–2777.
Press, M. F., Bernstain, L., Thomas, P. A., Meisner, L. F., Zhou, J. Y., Ma, Y., Hung, G., Robinson, R. A., Harris, C., El-Naggar, A., Slamon, D. J., Phillips, R. N., Ross, J. S., Wolman, S. R. & Flom, K. J. (1997). HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinoma. J Clin Oncol 15: 2894–2904.
Rilke, F., Colnaghi, M. I., Cascinelli, N., Andreola, S., Baldini, M. T., Bufalino, R., Della Porta, G., Menard, S., Pierotti, M. A. & Testori, A. (1991). Prognostic significance of c-erbB2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49: 44–49.
Rilke, F., Veronesi, U., Luini, A., Brambilla, C., Galimberti, V., Zurrida, S., Pilotti, S., Di Palma, S., Zucoli, R. & Lozza, L. (1996). Preoperative chemotherapy alone and combined with preoperative radiotherapy in small-size breast cancer. Breast 2: 176–180.
Sauter, G., Feichter, G., Torhorst, J., Moch, H., Novotna, H., Wagner, U., Durmuller, U. & Waldman, F. M. (1996). Fluorescence in situ hybridization for detecting ErbB-2 amplification in breast tumour fine needle aspiration biopsies. Acta Cytol 40: 164–173.
Sjogren, S., Inganas, M., Lindgren, A., Holmberg, L. & Bergh, J. (1998). Prognostic and predictive value of c-erB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16: 462–469.
Solomon, E., Borrow, J. & Goddard, A. (1991). Chromosome aberrations and cancer. Science 254: 1153–1160.
Troncone, G., Zeppa, P., Fulciniti, F., Di Benedetto, G., Lombresco, M. A., De Divitiis, B., Vetrani, A. & Palombini, L. (1993). c-erbB-2 expression and DNA ploidy status in breast cancer cells obtained by fine needle aspiration (FNA). Cytopathology 4: 195–205.
Troncone, G., Panico, L., Vetrani, A., de Divitiis, B., Zeppa, P., Fulciniti, F., Pettinato, G. & Palombini, L. (1996). c-erbB-2 expression in FNAB smears and matched surgical specimens of breast cancer. Diagn Cytopathol 14: 135–139.
Hermanek, P. & Sobin, L. H. (eds) (1992). TNM Classification of Malignant Tumours, 4th edn, pp. 103–109. Springer Verlag: Berlin
Von Hoff, D. D., McGill, J. R., Forseth, B. J., Davidson, K. K., Bradley, T. P., Van Devanter, D. R. & Wahl, G. M. (1992). Elimination of extrachromosomally amplified MYC genes from human tumour cells reduces their tumorigenicity. Proc Natl Acad Sci USA 89: 8165–8169.
Wahl, A. F., Donaldson, K. L., Fairchild, C., Lee, F. Y. F., Foster, S. A., Demers, G. W. & Galloway, D. A. (1996). Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat Med 2: 72–79.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Mezzelani, A., Alasio, L., Bartoli, C. et al. c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. Br J Cancer 80, 519–525 (1999). https://doi.org/10.1038/sj.bjc.6690387
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690387
Keywords
This article is cited by
-
Correlation of HER2 gene status assessment by fluorescence in situ hybridization between histological sections and cytological specimens of breast cancer
Breast Cancer (2016)
-
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity
Modern Pathology (2014)
-
PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade
Modern Pathology (2013)
-
Diagnostic value of fine-needle aspiration biopsy for breast mass: a systematic review and meta-analysis
BMC Cancer (2012)
-
Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome
Modern Pathology (2008)
